Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B, down 0.9% year over year. Operating margin was 0.6% and net margin -3.6%, on a free-cash-flow margin of 12.9% with capital expenditure at 5.5% of revenue. Every figure is computed directly from CRL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4.02B | 0.6% | -3.6% |
| FY2024 | $4.05B | 5.6% | 0.5% |
| FY2023 | $4.13B | 14.9% | 11.5% |
| FY2022 | $3.98B | 16.4% | 12.2% |
| FY2021 | $3.54B | 16.7% | 11.0% |
How does CRL compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: AACG · ABSI · ACCS · ACM · ADUS · AGL
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.